SAVSU Technologies Announces evo Smart Shipper Models with Thermal Autonomy of 15+ days

Press Release Summary:

  • evo DV7 maintains biologic payloads at a temperature of -196°C during storage and transport
  • Built with Fusion Core™, Smart Cap™, and Autonomous Payload Extractor™ technologies
  • ACS allows cell therapy companies to safely source incoming materials while providing a high degree of supply chain control

Original Press Release:

SAVSU Technologies Launches Two New evo® Smart Shipper Models to Improve Apheresis Collection Shipments and Cryopreserved Cell and Gene Therapies

evo ACS™ Extends Thermal Protection During Shipment of Patients' T Cells for Downstream Manufacturing of CAR T-Cell Therapies

Albuquerque, N.M., Jan. 22, 2019 /PRNewswire/ -- SAVSU Technologies, the leading developer of smart precision shipping containers and cloud-based cold chain management solutions, today announced a major product line expansion and extension, with the launch of two new shippers in its industry-best evo cold chain management system.

Today, at the Phacilitate Cell & Gene Therapy World Leaders conference in Miami, SAVSU introduced the evo ACS™ and the evo DV7™. The evo ACS is a category-breaking 2-8°C shipper specifically designed for shipping apheresis collections of live cells intended for downstream manufacturing of autologous cell therapies. A smart system with thermal autonomy of 15+ days, the ACS allows cell therapy companies to safely source incoming materials globally while providing a high degree of supply chain control. Built for the challenges of commercialization, the ACS, connected to the, is "always on" and does not require special training or "button pushing" by hospital staff to turn the device on, as is the case with other shipping containers.

Bruce McCormick, President of SAVSU, said, "The ACS is a game changer. It gives our cell and gene therapy customers an unprecedented degree of flexibility in designing systems for their fresh cells that reduce risk, increase intelligence, and can scale through commercialization. With the current awareness of the impact variability of apheresis collections can have on final cell quality and therapeutic efficacy, we believe evo ACS will be very well received and preferred by the leading cell therapy developers."

The new evo DV7 extends SAVSU's dry vapor shipper product line, which maintains biologic payloads at a temperature of -196°C during storage and transport. Positioned between the DV4 and the DV10, the DV7 offers 7 days of thermal autonomy in a compact unit, while maintaining a large payload size similar to the DV10. Like all other SAVSU DV shippers, the DV7 is built with SAVSU's proprietary Fusion Core™, Smart Cap™, and Autonomous Payload Extractor™ technologies.

Caitlin Rice, evo Product Manager, commented, "Our customers have been asking for a compact evo DV shipper with 7 days of autonomy. The DV7 retains the advantages of the DV10 unit in a more compact form factor. It's easier to handle, easier to store, and less expensive to ship. Since we design and build our evo shippers and cloud software, these new products represent our ability to respond to customer needs and quickly bring innovative products to market. Based on feedback from our early focus group customers, the DV7 could capture a significant share of the market for dry vapor shippers."

Savsu will be exhibiting at Phacilitate: Leaders World / World Stem Cell Summit in Miami, FL January 22-25. The ACS and DV7 units will be on display.

About SAVSU Technologies

SAVSU is a leading designer and manufacturer of innovative high-performance cloud-connected passive storage and transport containers for temperature sensitive biologics and pharmaceuticals. Our mission is to improve global health by greatly reducing the waste and risks associated with the improper freezing and overheating of thermal-sensitive medicines and biologics. SAVSU has developed proprietary state-of-the-art technology to ultimately lower costs and improve delivery of these most essential materials. BioLife Solutions (NASDAQ: BLFS), holds a 44% equity ownership position in SAVSU. For more information please visit

Source SAVSU Technologies


Media Relations, Dana Barnard, Chief Executive Officer,

Web Site:

All Topics